Skip to main content
Clinical Trials/ITMCTR2000003830
ITMCTR2000003830
Not yet recruiting
Phase 1

A randomized controlled clinical study on minimally invasive acupoint cat-embedding intervention for metabolic abnormalities of chronic kidney disease

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Chronic kidney disease
Sponsor
Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\. It conforms to the western medicine diagnostic criteria for stage 1\-3 chronic kidney disease, and according to the CKD staging criteria for stage 1\-3 (eGFR\>30 ml/min / 1\.73 m2\)
  • (CkD\-EPI formula:
  • Serum creatinine \<\=62 mol/L eGFR (ml/min/1\.73m2\) \=144x(SCR/62\) \-0\.329x0\.993Age
  • Serum creatinine \& gt; 62 mol/L eGFR (ml/min/1\.73m2\) \=144x(SCR / 62\)\-1\.209x0\.993Age
  • Serum creatinine \<\=80 mol/L eGFR (ml/min/1\.73m2\) \=141x(SCR/80\) \-0\.411 x 0\.993Age;
  • Serum creatinine \& gt;EGFR 80 mol/L (ml/min/1\.73m2\) \=141x(SCR / 80\)\- 1\.209x0\.993age;
  • 2\. Aged 18\-75 years old;
  • 3\. Diagnosis of metabolic syndrome (MS):
  • According to the international Diabetes Federation (IDF) standard and 2007 Chinese adult dyslipidemia prevention and Control guidelines, MS is defined as the presence of the following three or more components: Abdominal obesity, defined as waist circumference (WC measured from the midpoint between the lower rib and the anterior superior iliac spine) \>\=90cm for male and 85cm for female;Hypertriglyceridemia, defined as serum triglyceride concentration \>\= 1\.70mmol /L,Low high\-density lipoprotein cholesterol, defined as serum high\-density lipoprotein cholesterol concentration HDL\-C\& LT; 1\.04 the tendency for L; Hypertension, defined as systolic blood pressure (SBP)\>\=130 mm Hg, diastolic blood pressure (DBP)\>\=85 mm Hg, or treated with blood pressure lowering drugs; High fasting blood glucose \>\=6\.1mmol/L or glucose load \>\=7\.8mmol /L 2 h after meal or diabetes history;
  • 4\. Those who voluntarily accept the drug treatment and sign the informed consent.

Exclusion Criteria

  • 1\) Patients who are allergic to acupuncture or wire embedding, or patients who are known to be allergic to the drugs used;
  • 2\) Patients with severe primary diseases such as heart, brain, liver and hematopoietic system;
  • 3\) Patients with acute metabolic disorders such as diabetic ketoacidosis within the past month;
  • 4\) Acute renal failure patients, associated with urinary tract infection, menstrual period, intense exercise, cold and other stress states;
  • 5\) Mentally ill patients, pregnant or lactating women;
  • 6\) Those who are participating in other drug clinical trials or have participated in other clinical trials within 3 months.

Outcomes

Primary Outcomes

Not specified

Similar Trials